Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN027
MIFTS: 57

Adenomyosis

Categories: Muscle diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Adenomyosis

About this section

MalaCards integrated aliases for Adenomyosis:

Name: Adenomyosis 56 12 74 52 43 15 17
Endometriosis of Uterus 12 15 71 32
Endometriosis of Myometrium 12
Endometriosis, Myometrium 12
Endometriosis Interna 12
Uterine Adenomyosis 12

Characteristics:

OMIM:

56
Inheritance:
autosomal vs. x-linked dominant


HPO:

31
adenomyosis:
Inheritance autosomal dominant inheritance x-linked dominant inheritance


Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Reproductive diseases Muscle diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:288
OMIM 56 600458
ICD9CM 34 617.0
MeSH 43 D062788
NCIt 49 C6996
SNOMED-CT 67 76376003
ICD10 32 N80.0
MedGen 41 C0341858
UMLS 71 C0341858
Sources

Summaries for Adenomyosis

About this section
NIH Rare Diseases : 52 Adenomyosis is a condition that affects the uterus. In women with adenomyosis, the endometrial tissue (which typically lines the uterus) moves into the outer, muscular walls of the uterus. Some women may have no signs or symptoms of the condition. When present, features of the condition include heavy menstrual bleeding, painful menstrual periods, and pelvic pain during intercourse. Some women may also develop an adenomyoma, which is a mass or growth within the uterus. The underlying cause of the condition is currently unknown. In general, treatment is based on the signs and symptoms present in each person. Forms of birth control that contain progesterone (such as birth control pills or an IUD) may decrease heavy bleeding while certain medications can be used to manage pain. In severe cases, a hysterectomy may be recommended.

MalaCards based summary : Adenomyosis, also known as endometriosis of uterus, is related to uterine anomalies and leiomyoma. An important gene associated with Adenomyosis is PGR (Progesterone Receptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Acetaminophen and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include uterus, breast and bone, and related phenotypes are abnormal bleeding and dysmenorrhea

Disease Ontology : 12 A uterine disease that is characterized by the presence of endometrial tissue grows outside of the endometrium, such as into the myometrium.

OMIM : 56 Adenomyosis is characterized by the presence of endometrial glands and stroma within the myometrium. Abnormal uterine bleeding and dysmenorrhea are the most characteristic symptoms, occurring in approximately 65% of cases (Arnold et al., 1995). (600458)

Wikipedia : 74 Adenomyosis is a gynecologic medical condition characterized by the abnormal presence of endometrial... more...

Sources

Related Diseases for Adenomyosis

About this section

Diseases related to Adenomyosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 460)
# Related Disease Score Top Affiliating Genes
1 uterine anomalies 32.5 TP53 PGR ESR1 CYP19A1
2 leiomyoma 31.0 PGR OXTR MME GNRH1 ESR1 CYP19A1
3 amenorrhea 30.9 PRL GNRH1 CYP19A1
4 endometriosis of ovary 30.9 PGR GNRH1 ESR1 CYP19A1
5 ovarian cyst 30.9 VEGFA PRL GNRH1 CYP19A1
6 adenomyoma 30.9 PGR MME GNRH1 ESR1 CTNNB1
7 leiomyomatosis 30.7 PGR GNRH1 ESR1
8 intravenous leiomyomatosis 30.7 PGR MME ESR1
9 leiomyosarcoma 30.6 VEGFA TP53 PGR ESR1
10 endometrial adenocarcinoma 30.5 VEGFA TP53 PGR ESR1 CTNNB1 CDH1
11 infertility 30.3 PRL PGR LIF HOXA10 GNRH1 CYP19A1
12 endometrial hyperplasia 30.3 VEGFA TP53 PGR HOXA10 ESR1 CYP19A1
13 endometritis 30.3 PGR OXT ESR1 CXCL8
14 adenosarcoma 30.2 TP53 PGR MME ESR1
15 in situ carcinoma 30.2 TP53 PGR ESR1 CYP19A1 CDH1
16 smooth muscle tumor 30.2 PGR MME ESR1
17 endosalpingiosis 30.2 TP53 PGR ESR1
18 placenta disease 30.2 VEGFA OXT CXCL8
19 adenocarcinoma 30.2 VEGFA TP53 TIMP2 PTGS2 MMP9 MMP2
20 ovarian hyperstimulation syndrome 30.2 VEGFA GNRH1 CYP19A1
21 pain agnosia 30.2 PTGS2 OXT NGF
22 clear cell adenocarcinoma 30.2 TP53 PGR HOXA10 ESR1
23 pre-eclampsia 30.1 VEGFA OXT MMP9 MMP2 CXCL8
24 preterm premature rupture of the membranes 30.1 TIMP2 OXT MMP9 MMP2 CXCL8
25 ectopic pregnancy 30.1 VEGFA PGR LIF HOXA10 GNRH1
26 leiomyoma, uterine 30.1 PGR OXTR OXT MMP2 GNRH1 ESR1
27 female reproductive endometrioid cancer 30.0 TP53 PGR ESR1 CTNNB1
28 papillary adenocarcinoma 30.0 TP53 PGR CDH1
29 ureteral obstruction 30.0 TP53 PTGS2 CTNNB1
30 endometriosis 30.0 VEGFA PTGS2 PGR MMP2 LIF HOXA10
31 myoma 30.0 PGR OXT MME HOXA10 GNRH1 ESR1
32 interstitial cystitis 30.0 VEGFA NGF CXCL8 CDH1
33 pelvic organ prolapse 29.9 TP53 PGR MMP9 MMP2 ESR1
34 estrogen excess 29.8 PRL PGR GNRH1 ESR1 CYP19A1
35 tubular adenocarcinoma 29.7 PGR MME ESR1 CTNNB1 CDH1
36 vaginal discharge 29.7 PGR OXT GNRH1 ESR1 CYP19A1 CXCL8
37 hydronephrosis 29.7 VEGFA MMP9 MME CYP19A1 CXCL8
38 cystitis 29.5 VEGFA TP53 PTGS2 NGF CXCL8 CDH1
39 wilms tumor 1 29.5 VEGFA TP53 PGR ESR1 CTNNB1 CDH1
40 carcinosarcoma 29.4 TP53 PGR MME CTNNB1 CDH1
41 breast fibroadenoma 29.3 TP53 TIMP2 PGR MME ESR1 CYP19A1
42 endometrial disease 29.3 PTGS2 PGR OXT HOXA10 ESR1 CYP19A1
43 endometrial stromal sarcoma 29.3 TP53 PGR OXTR MMP9 MMP2 MME
44 uterine carcinosarcoma 29.1 VEGFA TP53 PTGS2 PGR MME ESR1
45 endometrial cancer 28.7 VEGFA TP53 TIMP2 PGR MMP9 MMP2
46 cervical cancer 28.7 VEGFA TP53 PTGS2 MMP9 MMP2 ESR1
47 ovarian cancer 27.2 VEGFA TP53 TIMP2 PTGS2 PGR MMP9
48 extracranial arteriovenous malformation 10.6 MMP9 MMP2
49 glassy cell carcinoma of the cervix 10.6 PGR ESR1
50 bartholin's gland adenoid cystic carcinoma 10.6 PGR ESR1

Graphical network of the top 20 diseases related to Adenomyosis:



Diseases related to Adenomyosis
Sources

Symptoms & Phenotypes for Adenomyosis

About this section

Human phenotypes related to Adenomyosis:

31
# Description HPO Frequency HPO Source Accession
1 abnormal bleeding 31 HP:0001892
2 dysmenorrhea 31 HP:0100607
3 abnormality of the genitourinary system 31 HP:0000119

Symptoms via clinical synopsis from OMIM:

56
Lab:
dysmenorrhea
endometrial glands and stroma within the myometrium
abnormal uterine bleeding

G U:
adenomyosis

Clinical features from OMIM:

600458

MGI Mouse Phenotypes related to Adenomyosis:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.5 CTNNB1 CYP19A1 ESR1 HOXA10 LIF MME
2 homeostasis/metabolism MP:0005376 10.48 CDH1 CTNNB1 CYP19A1 ESR1 GNRH1 LIF
3 cardiovascular system MP:0005385 10.47 CDH1 CTNNB1 CYP19A1 ESR1 HOXA10 LIF
4 growth/size/body region MP:0005378 10.44 CDH1 CTNNB1 CYP19A1 ESR1 GNRH1 HOXA10
5 integument MP:0010771 10.43 CDH1 CTNNB1 CYP19A1 ESR1 GNRH1 LIF
6 endocrine/exocrine gland MP:0005379 10.42 CDH1 CTNNB1 CYP19A1 ESR1 GNRH1 HOXA10
7 immune system MP:0005387 10.41 CDH1 CTNNB1 CYP19A1 ESR1 GNRH1 LIF
8 digestive/alimentary MP:0005381 10.36 CDH1 CTNNB1 CYP19A1 ESR1 GNRH1 HOXA10
9 nervous system MP:0003631 10.36 CTNNB1 CYP19A1 ESR1 GNRH1 HOXA10 LIF
10 hematopoietic system MP:0005397 10.34 CTNNB1 CYP19A1 ESR1 GNRH1 LIF MMP2
11 muscle MP:0005369 10.26 CTNNB1 CYP19A1 ESR1 LIF MMP2 MMP9
12 neoplasm MP:0002006 10.2 CDH1 CTNNB1 ESR1 GNRH1 MMP2 MMP9
13 liver/biliary system MP:0005370 10.19 CTNNB1 CYP19A1 ESR1 GNRH1 LIF MME
14 normal MP:0002873 10.18 CDH1 CTNNB1 CYP19A1 ESR1 GNRH1 MMP2
15 adipose tissue MP:0005375 10.15 CYP19A1 ESR1 HOXA10 LIF OXT PTGS2
16 reproductive system MP:0005389 10.13 CDH1 CTNNB1 CYP19A1 ESR1 GNRH1 HOXA10
17 no phenotypic analysis MP:0003012 10.06 CDH1 CTNNB1 ESR1 NGF OXTR PGR
18 limbs/digits/tail MP:0005371 10.05 CTNNB1 ESR1 HOXA10 MMP9 PGR TP53
19 renal/urinary system MP:0005367 9.97 CTNNB1 CYP19A1 ESR1 GNRH1 MMP9 OXT
20 respiratory system MP:0005388 9.76 CTNNB1 ESR1 LIF MMP2 MMP9 PTGS2
21 skeleton MP:0005390 9.73 CTNNB1 CYP19A1 ESR1 GNRH1 HOXA10 LIF
22 vision/eye MP:0005391 9.28 CTNNB1 CYP19A1 LIF MMP2 MMP9 NGF
Sources

Drugs & Therapeutics for Adenomyosis

About this section

Drugs for Adenomyosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 118)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Ibuprofen Approved Phase 4 15687-27-1 3672
3
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
4
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
5
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
6
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
7
Dienogest Approved Phase 4 65928-58-7
8
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
9
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
10
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
Polyestradiol phosphate Approved Phase 4 28014-46-2
13
Norethindrone Approved Phase 4 68-22-4 6230
14
Buserelin Approved, Investigational Phase 4 57982-77-1
15
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
16
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
17
Nandrolone Experimental, Investigational Phase 4 434-22-0 9904
18
Deslorelin Investigational, Vet_approved Phase 4 57773-65-6
19 Antipyretics Phase 4
20 Aromatase Inhibitors Phase 4
21 Estrogen Antagonists Phase 4
22 Steroid Synthesis Inhibitors Phase 4
23 Estrogen Receptor Antagonists Phase 4
24 Anti-Inflammatory Agents Phase 4
25 Analgesics Phase 4
26 Anti-Inflammatory Agents, Non-Steroidal Phase 4
27 Analgesics, Non-Narcotic Phase 4
28 Cyclooxygenase Inhibitors Phase 4
29 Antirheumatic Agents Phase 4
30 Oxytocics Phase 4
31 Estrogens Phase 4
32 Hormone Antagonists Phase 4
33 Hormones Phase 4
34 Anabolic Agents Phase 4
35 Contraceptives, Oral, Combined Phase 4
36 Androgens Phase 4
37 Estradiol 17 beta-cypionate Phase 4
38 Estradiol 3-benzoate Phase 4
39 Triptorelin Pamoate Phase 4
40 Prolactin Release-Inhibiting Factors Phase 4
41 Norethindrone Acetate Phase 4
42 Antineoplastic Agents, Hormonal Phase 4
43 Contraceptives, Oral Phase 4
44 Contraceptive Agents, Male Phase 4
45 Progestins Phase 4
46
Medroxyprogesterone Phase 4 520-85-4 10631
47
Levonorgestrel Approved, Investigational Phase 3 797-63-7, 17489-40-6 13109
48
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
49
Goserelin Approved Phase 2, Phase 3 65807-02-5, 1233494-97-7 47725 5311128
50
Mifepristone Approved, Investigational Phase 2, Phase 3 84371-65-3 55245

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
2 A Controlled Trial on Uterine Fibroids Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus Ulipristal Acetate Recruiting NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
3 Mechanistic Characterization of Uterine Pain (MCUP) to Improve Diagnosis and Treatment for Dysmenorrhea Recruiting NCT04145518 Phase 4 Naproxen Sodium
4 Use of Oxytocin in MRI-HIFU Treatment Enrolling by invitation NCT03937401 Phase 4 Oxytocin
5 Role of Dienogest in the Treatment of Patient With Symptomatic Adenomyosis Not yet recruiting NCT03654144 Phase 4 Dienogest;Combined Oral Contraceptive
6 Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer. Not yet recruiting NCT03946722 Phase 4 GnRH analogue downregulation
7 Initiation of Medical Menopause With Depot Leuprolide Acetate vs Depot Leuprolide Acetate Plus Medroxyprogesterone Acetate: A Pilot Randomized Terminated NCT01776203 Phase 4 Medroxyprogesterone 17-Acetate
8 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
9 Uterine Artery Doppler and Three Dimensional Power Doppler in the Diagnosis of Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
10 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
11 Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis Unknown status NCT01483417 Phase 3
12 Efficacy of Food Supplements Containing Trace Elements in the Treatment of Endometriosis, Combined or Not to an Adenomyosis: a Pilot Study Unknown status NCT02437175 Phase 3
13 Maintenance Therapy of LNG-IUS in Conjunction With the GnRH Agonist to Prevent the Recurrence of Symptomatic Endometriosis After Conservative Surgery: A Prospective Randomized, Phase III Trial Unknown status NCT01125488 Phase 3 GnRH agonist (triptorelin)
14 To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial Unknown status NCT01048931 Phase 3
15 Aromatase Inhibitors or Gonadotropin-releasing Hormone Agonists for the Management of Uterine Adenomyosis: A Randomized Controlled Trial Completed NCT01218581 Phase 2, Phase 3 received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
16 Mifepristone Versus Placebo to Treat Adenomyosis: a Double-blind, Multicentre，Randomized Clinical Trial Completed NCT03520439 Phase 2, Phase 3 Mifepristone;Placebo
17 Randomized Controlled Study of Different Pain Scores in Single-Port Access (SPA) Laparoscopic Hysterectomy Versus Conventional Laparoscopic Hysterectomy Completed NCT01064128 Phase 3
18 Effect of Elastic Abdominal Binder on Pain and Functional Recovery After Open Abdominal Surgery for Benign Gynecologic Conditions: a Randomized Controlled Trial Recruiting NCT03820115 Phase 3
19 Phase III Trial to Assess Impact of Ultra-long Versus Long Down-regulation Protocol on IVF/ICSI Outcomes in Infertile Women Presenting With Adenomyosis. Not yet recruiting NCT03940807 Phase 3 11.25mg GnRH agonist;0.1 mg GnRH agonist;25 µg transdermal oestradiol
20 Pilot Phase II, Randomized , and Control in Double Blind Placebo Effectiveness a 3 Months on Bleeding Fibroids Treatment With ULIPRISTAL ACETATE 10 mg/Day in Patients Suffering From Symptomatic Endometriosis Unknown status NCT02587000 Phase 2 Ulipristal acetate;Placebo
21 Surgicel® Versus Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding (HMB): Randomised Controlled Trial Unknown status NCT03176992 Phase 2 SURGICEL®
22 Levonorgestrel-releasing Intrauterine System Compared to Low Dose Combined Oral Contraceptive Pills for Treatment of Adenomyosis: a Randomized Controlled Trial Completed NCT01601366 Phase 2 Combined oral contraceptives
23 Tactile Versus Hysteroscopic Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding Completed NCT02248194 Phase 2
24 A Randomised, Double-blind, Placebo-controlled, Proof-of-mechanism Phase 2 Trial Investigating the Effect of Quinagolide Extended-release Vaginal Ring on Reduction of Lesions Assessed by High-resolution Magnetic Resonance Imaging in Women With Endometrioma, Deep Infiltrating Endometriosis, and/or Adenomyosis Recruiting NCT03749109 Phase 2 Quinagolide 1080 µg;Placebo
25 A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Proof of Concept Study With an Interim Futility Analysis of Epelsiban in Patients With Adenomyosis Withdrawn NCT02794467 Phase 2 Epelsiban;Placebo
26 Vaginal Bromocriptine for the Treatment of Adenomyosis Completed NCT01821001 Phase 1 Vaginal Bromocriptine
27 Proliferation of Endometrial Stromal Cells in Adenomyosis Unknown status NCT00173212
28 Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis Unknown status NCT00172588
29 Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS) Unknown status NCT02556411 LNG-IUS 13,5 mg Levonorgestrel;Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg
30 Progestin Treatment for Endometrial Stromal Cells in Adenomyosis Unknown status NCT00155051
31 Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri Unknown status NCT03037944 Early Phase 1 Yasmin
32 Health-Related Quality of Life Among Women Receiving Hysterectomy in National Taiwan University Hospital Unknown status NCT00155870
33 Efficacy of Acupuncture on Chronic Pelvic Pain in Women With Endometriosis or Adenomyosis : A Preliminary Study Unknown status NCT01259180
34 Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis Unknown status NCT03006406 Long term GnRH-a (3.75mg)
35 Prospective Cohort Study to Compare to 2-channel and Multiple Channel Single Port Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01564602
36 The Impact of Gynecological Surgery on Ovarian Function in Women of Reproductive Age: Postoperative Changes of Serum Anti-Müllerian Hormone Unknown status NCT00928044
37 Acceptability and Tolerance of Hysteroscopy and Hysterosonography in Consultation Unknown status NCT03121560
38 The Effect in Term of Ovarian Reserve Modification of Adding Prophylactic Bilateral Salpingectomy (PBS) to TLH for Preventing Ovarian Cancer Unknown status NCT02086344
39 "Estudio de Histerosalpingografía Por Resonancia Magnética Para la evaluación Integral de la Paciente infértil." Unknown status NCT02398630
40 What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography Completed NCT01992718 Early Phase 1
41 Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio Can Be Useful Markers for Distinguishing Uterine Adenomyosis and Leiomyoma Completed NCT02997787
42 The Diagnostic Accuracy of Hysteroscopic Endomyometrial Biopsy in Adenomyosis Completed NCT02340533
43 Cohort Study of Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis Completed NCT03027648
44 Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnostics, Part I Completed NCT02201719
45 Can the Effect of Levonorgestrel Intrauterine System for Treatment of Adenomyosis be Predicted at Baseline Visit? Completed NCT03104309
46 Comparison of the Operation and Medical Treatment of Endometriosis and Adenomyosis Completed NCT03778359 Leuprorelin;Dienogest;Progestins
47 Short and Long Term Outcomes of Uterine Artery Embolization. Completed NCT00354471
48 Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy: a Randomized, Single-Blinded Study Comparing the Efficacy to the Routine Procedure Completed NCT01806012
49 The Effect of Dexamethasone on Inflammatory Response After Uterine Artery Embolization Completed NCT02056717 Dexamethasone;Normal saline
50 Use of the Electronic Catheter Stethoscope for the Detection of Urinary Tract Injury During Gynecologic Surgery Completed NCT01463462

Search NIH Clinical Center for Adenomyosis

Cochrane evidence based reviews: adenomyosis

Sources

Genetic Tests for Adenomyosis

About this section
Sources

Anatomical Context for Adenomyosis

About this section

MalaCards organs/tissues related to Adenomyosis:

40
Uterus, Breast, Bone, Ovary, Pituitary, Cervix, Kidney
Sources

Publications for Adenomyosis

About this section

Articles related to Adenomyosis:

(show top 50) (show all 2576)
# Title Authors PMID Year
1
Adenomyosis: evidence for genetic cause. 61 56
7762596 1995
2
The elusive adenomyosis of the uterus. Its historical past and its present state of recognition. 61 56
13890115 1962
3
Classification and Reporting Systems for Adenomyosis. 61
31785418 2020
4
Adenomyosis and pregnant uterus: An alliance doomed to rupture? 61
31499284 2020
5
Imaging for Adenomyosis: Making the Diagnosis by Sonography. 61
31610319 2020
6
Asherman syndrome in adenomyosis treated with uterine artery embolization: incidence predictive factors. 61
32020527 2020
7
Question Mark Sign and Transvaginal Ultrasound Uterine Tenderness for the Diagnosis of Adenomyosis: A Prospective Validation. 61
32030800 2020
8
Association between Preoperative Adenomyosis Detection Rate during Pelvic Ultrasonography and the Specialty of the Reading Physician. 61
31004795 2020
9
A Systematic Review of Tissue Sampling Techniques for the Diagnosis of Adenomyosis. 61
31499191 2020
10
Noninvasive Diagnosis of Adenomyosis: A Structured Review and Meta-analysis of Diagnostic Accuracy in Imaging. 61
31712162 2020
11
An Abundance of Studies But Dearth of Evidence regarding Endometriosis and Adenomyosis. 61
31812611 2020
12
Is High-intensity Focused Ultrasound Effective for the Treatment of Adenomyosis? A Systematic Review and Meta-analysis. 61
31377454 2020
13
The Outcome of Fertility-Sparing and Nonfertility-Sparing Surgery for the Treatment of Adenomyosis. A Systematic Review and Meta-analysis. 61
31398415 2020
14
The importance of the junctional zone of the endometrium in human reproduction. 61
32024409 2020
15
Safety and efficacy of contained manual morcellation during laparoscopic or robotic gynecological surgery. 61
31755560 2020
16
Abnormal uterine inflammation in obstetric syndromes: molecular insights into the role of chemokine decoy receptor D6 and inflammasome NLRP3. 61
32030415 2020
17
Patient perceptions of misdiagnosis of endometriosis: results from an online national survey. 61
32007945 2020
18
Ultrasound assessment of uterine morphology in menorrhagia: case control study. 61
31352859 2020
19
Ultrasonographic soft markers for detection of rectosigmoid deep endometriosis. 61
30977185 2020
20
Sonographic Evaluation for Endometriosis in Routine Pelvic Ultrasound. 61
31493569 2020
21
A new trick for an old dog: The application of mifepristone in the treatment of adenomyosis. 61
31814282 2020
22
The new application of mifepristone in the relief of adenomyosis-caused dysmenorrhea. 61
32038106 2020
23
ADENOMYOSIS INCIDENCE, PREVALENCE AND TREATMENT: UNITED STATES POPULATION-BASED STUDY 2006-2015. 61
31954156 2020
24
Coexistence of uterine adenomyosis is not associated with a better prognosis in endometrioid-type endometrial cancer. 61
31970616 2020
25
Comparison between microwave ablation and radiofrequency ablation for treating symptomatic uterine adenomyosis. 61
32024402 2020
26
Pregnancy and symptomatic relief following ultrasound-guided transvaginal radiofrequency ablation in patients with adenomyosis. 61
31646731 2020
27
Mechanisms Underlying Adenomyosis-Related Fibrogenesis. 61
31487711 2020
28
Endometriosis and Pregnancy: A Single Institution Experience. 61
31936225 2020
29
The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ. 61
31954395 2020
30
Study of causes behind abnormal uterine bleeding according to PALM- COEIN classification at a tertiary care hospital. 61
31954043 2020
31
Factors associated with physiological postoperative pyrexia. 61
31762178 2020
32
Endometriosis of the Appendix: When to Predict and How to Manage-A Multivariate Analysis of 1935 Endometriosis Cases. 61
30849476 2020
33
Junctional Zone Endometrium Morphological Characteristics and Functionality: Review of the Literature. 61
31968333 2020
34
Impact of evaluation in interventional radiology clinic prior to uterine artery embolization: changes in management. 61
31897679 2020
35
Giant exophytic cystic adenomyosis with a levonorgestrel containing intrauterine device out of the uterine cavity after uterine myomectomy: A case report. 61
31970186 2020
36
Surgical Management of Cesarean Scar Defect: The Hysteroscopic-Assisted Robotic Single-Site Technique. 61
31220602 2020
37
Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. 61
31857578 2019
38
Transvaginal ultrasound-guided biopsy of adenomyosis. 61
32016059 2019
39
Correction to: Differences in the clinical phenotype of adenomyosis and leiomyomas: a retrospective, questionnaire-based study. 61
31463612 2019
40
Expression of Lewis (b) blood group antigen interferes with oral dienogest therapy among women with adenomyosis. 61
31927399 2019
41
Nonpuerperal uterine inversion due to adenomyosis: A case report and a literature review. 61
31893073 2019
42
Expression of Cannabinoid Receptors in Myometrium and its Correlation With Dysmenorrhea in Adenomyosis. 61
30832539 2019
43
Transcriptome sequencing of adenomyosis eutopic endometrium: A new insight into its pathophysiology. 61
31576674 2019
44
[Cervical injury during surgery for rectovaginal deep infiltrating endometriosis with external adenomyosis  (with video)]. 61
31589930 2019
45
Safety and Efficacy of Ultrasound-Guided High-Intensity Focused Ultrasound Treatment for Uterine Fibroids and Adenomyosis. 61
31563479 2019
46
The role of levonorgestrel intra-uterine system in the management of adenomyosis: A systematic review and meta-analysis of prospective studies. 61
31889294 2019
47
Effect of ovarian steroids on vascular endothelial growth factor a expression in bovine uterine endothelial cells during adenomyosis. 61
31888628 2019
48
Elasticity of adenomyosis is increased after GnRHa therapy and is associated with spontaneous pregnancy in infertile patents. 61
31067498 2019
49
Diagnosing adenomyosis with MRI: a prospective study revisiting the junctional zone thickness cutoff of 12 mm as a diagnostic marker. 61
31264010 2019
50
Junctional zone endometrium alterations in gynecological and obstetrical disorders and impact on diagnosis, prognosis and treatment. 61
31573995 2019
Sources

Variations for Adenomyosis

About this section
Sources

Expression for Adenomyosis

About this section
Search GEO for disease gene expression data for Adenomyosis.
Sources

Pathways for Adenomyosis

About this section

Pathways related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 47)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.01 VEGFA TP53 TIMP2 PTGS2 PRL MMP9
2
ERK Signaling 63
Show member pathways
 13.75 VEGFA TP53 TIMP2 PTGS2 NGF LIF
3
GPCR Pathway 63
Show member pathways
 13.69 VEGFA TP53 TIMP2 PTGS2 NGF MMP9
4
TGF-Beta Pathway 63
Show member pathways
 13.54 VEGFA TP53 TIMP2 PRL NGF GNRH1
5
Cytokine Signaling in Immune system 65
Show member pathways
 13.33 VEGFA TP53 PTGS2 PRL MMP9 MMP2
6
PAK Pathway 63
Show member pathways
 13.3 TIMP2 NGF LIF GNRH1 CXCL8 CTNNB1
7
Nanog in Mammalian ESC Pluripotency 63
Show member pathways
 13.27 VEGFA TIMP2 NGF GNRH1 ESR1 CTNNB1
8
PI3K-Akt signaling pathway 36
Show member pathways
 12.97 VEGFA TP53 PTGS2 PRL NGF CTNNB1
9
Gastric cancer 36
Show member pathways
 12.75 TP53 PGR ESR1 CTNNB1 CDH1
10
Relaxin signaling pathway 36
Show member pathways
 12.67 VEGFA PGR MMP9 MMP2 ESR1
11
Development HGF signaling pathway 22
Show member pathways
 12.67 TP53 PTGS2 NGF ESR1 CTNNB1 CDH1
12
Glioma 36
Show member pathways
 12.66 TP53 MMP9 MMP2 ESR1 CDH1
13
Pathways in cancer 36
12.64 VEGFA TP53 PTGS2 MMP9 MMP2 ESR1
14
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.39 VEGFA PTGS2 ESR1 CTNNB1
15
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.39 TIMP2 NGF GNRH1 CTNNB1 CDH1
16
Transcriptional misregulation in cancer 36
12.25 TP53 MMP9 HOXA10 CXCL8
17
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.25 TP53 TIMP2 NGF GNRH1 CXCL8
18
Proteoglycans in cancer 36
12.22 VEGFA TP53 MMP9 MMP2 ESR1 CTNNB1
19
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.16 VEGFA NGF CXCL8 CTNNB1
20
Integrated Breast Cancer Pathway 1
12.03 VEGFA TP53 ESR1 CYP19A1 CTNNB1 CDH1
21
Fluid shear stress and atherosclerosis 36
12.02 VEGFA TP53 MMP9 MMP2 CTNNB1
22
Adhesion 4
12 MMP9 MMP2 CTNNB1 CDH1
23
Spinal Cord Injury 1
11.98 TP53 PTGS2 MMP9 CXCL8
24
Colorectal Cancer Metastasis 63
11.92 VEGFA TP53 PTGS2 MMP9 MMP2 CTNNB1
25
Angiogenesis (CST) 4
11.8 TIMP2 PTGS2 MMP9 MMP2
26
Glucocorticoid receptor regulatory network 1
11.79 TP53 PRL CXCL8
27
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.7 MMP9 MMP2 CXCL8 CTNNB1 CDH1
28
Transcription_P53 signaling pathway 22
11.69 VEGFA TP53 MMP2 CTNNB1
29
LPA receptor mediated events 1
11.67 MMP9 MMP2 CXCL8
30
Lung fibrosis 1
11.66 MMP9 MMP2 CXCL8
31
Cell adhesion_ECM remodeling 22
11.61 TIMP2 MMP9 MMP2 CXCL8
32
Celecoxib Pathway, Pharmacodynamics 60
11.57 VEGFA PTGS2 MMP9 CTNNB1
33
Interleukin-10 signaling 65
11.52 PTGS2 LIF CXCL8
34
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.52 VEGFA PTGS2 MMP9 MMP2 CXCL8
35
Aryl Hydrocarbon Receptor 1
11.51 VEGFA PTGS2 ESR1
36
Hepatitis C and Hepatocellular Carcinoma 1
11.5 VEGFA TP53 PTGS2 CXCL8
37
Photodynamic therapy-induced HIF-1 survival signaling 1
11.37 VEGFA TP53 PTGS2
38
Signaling mediated by p38-alpha and p38-beta 1
11.33 TP53 PTGS2 ESR1
39
Bladder cancer 36 1
11.3 VEGFA TP53 MMP9 MMP2 CXCL8 CDH1
40
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.29 MMP9 MMP2 LIF CXCL8
41
A-beta Pathways: Uptake and Degradation 64
11.27 MMP9 MMP2 MME
42
Interleukin-4 and 13 signaling 65
11.22 VEGFA TP53 PTGS2 MMP9 MMP2 LIF
43
Plasma membrane estrogen receptor signaling 1
11.17 MMP9 MMP2 ESR1
44
Angiogenesis (WikiPathways) 1
11.13 VEGFA TIMP2 MMP9
45
A-beta Pathways: Plaque Formation and APP Metabolism 64
11.11 MMP9 MMP2 MME
46
G-protein signaling_Rap2B regulation pathway 22
11 TIMP2 NGF LIF GNRH1 CXCL8 CDH1
47
Aromatase Inhibitor Pathway (Breast Cell), Pharmacodynamics 60
10.23 ESR1 CYP19A1
Sources

GO Terms for Adenomyosis

About this section

Cellular components related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 VEGFA TIMP2 PRL OXT NGF MMP9
2 cell-cell adherens junction GO:0005913 9.46 VEGFA OXTR CTNNB1 CDH1
3 extracellular space GO:0005615 9.32 VEGFA TIMP2 PRL OXT NGF MMP9
4 flotillin complex GO:0016600 9.26 CTNNB1 CDH1

Biological processes related to Adenomyosis according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 VEGFA TP53 PGR LIF HOXA10 ESR1
2 positive regulation of gene expression GO:0010628 10.06 VEGFA TP53 NGF LIF CTNNB1
3 positive regulation of apoptotic process GO:0043065 10 TP53 PTGS2 NGF MMP9 CTNNB1
4 heart development GO:0007507 9.98 TP53 OXTR OXT CTNNB1
5 regulation of gene expression GO:0010468 9.98 HOXA10 GNRH1 CTNNB1 CDH1
6 angiogenesis GO:0001525 9.98 VEGFA PTGS2 MMP2 CXCL8
7 aging GO:0007568 9.92 TIMP2 PTGS2 MME GNRH1
8 negative regulation of gene expression GO:0010629 9.91 VEGFA TP53 PGR ESR1 CTNNB1
9 negative regulation of apoptotic process GO:0043066 9.91 VEGFA TP53 PTGS2 NGF MMP9 GNRH1
10 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.84 VEGFA PTGS2 NGF
11 response to organic cyclic compound GO:0014070 9.84 PTGS2 OXTR OXT GNRH1
12 extracellular matrix disassembly GO:0022617 9.82 TIMP2 MMP9 MMP2
13 response to peptide hormone GO:0043434 9.81 OXTR OXT GNRH1
14 response to cytokine GO:0034097 9.81 TIMP2 PTGS2 OXTR
15 response to drug GO:0042493 9.8 TP53 TIMP2 PTGS2 OXTR CTNNB1 CDH1
16 lung development GO:0030324 9.78 VEGFA MME LIF CTNNB1
17 female pregnancy GO:0007565 9.76 PRL OXTR OXT GNRH1
18 lactation GO:0007595 9.75 VEGFA PRL OXTR
19 cellular response to reactive oxygen species GO:0034614 9.73 TP53 MMP9 MMP2
20 memory GO:0007613 9.73 PTGS2 OXTR OXT NGF
21 mammary gland development GO:0030879 9.72 PRL PGR CYP19A1
22 response to steroid hormone GO:0048545 9.7 OXTR OXT GNRH1
23 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.67 TP53 ESR1
24 regulation of neuroinflammatory response GO:0150077 9.67 PTGS2 MMP9
25 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.66 TP53 ESR1
26 entry of bacterium into host cell GO:0035635 9.65 CTNNB1 CDH1
27 response to prostaglandin E GO:0034695 9.65 OXT GNRH1
28 positive regulation of uterine smooth muscle contraction GO:0070474 9.63 OXTR OXT
29 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.62 VEGFA TP53
30 negative regulation of gastric acid secretion GO:0060455 9.61 OXTR OXT
31 cellular response to indole-3-methanol GO:0071681 9.6 CTNNB1 CDH1
32 positive regulation of penile erection GO:0060406 9.59 OXTR OXT
33 sperm ejaculation GO:0042713 9.58 OXTR OXT
34 uterus development GO:0060065 9.58 HOXA10 ESR1 CYP19A1
35 positive regulation of norepinephrine secretion GO:0010701 9.57 OXTR OXT
36 embryo implantation GO:0007566 9.56 PTGS2 MMP9 MMP2 LIF
37 response to estradiol GO:0032355 9.55 PTGS2 OXTR OXT ESR1 CTNNB1
38 cytokine-mediated signaling pathway GO:0019221 9.5 VEGFA TP53 PTGS2 MMP9 MMP2 LIF
39 regulation of digestive system process GO:0044058 9.49 OXTR OXT
40 negative regulation of cell proliferation GO:0008285 9.23 TP53 TIMP2 PTGS2 NGF LIF GNRH1

Molecular functions related to Adenomyosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.35 TP53 PTGS2 PGR ESR1 CTNNB1
2 zinc ion binding GO:0008270 9.17 TP53 TIMP2 PGR MMP9 MMP2 MME
Sources

Sources for Adenomyosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....